John Dyer
Seminars
Wednesday 27th January 2027
Panel Discussion: Where Are Investors Placing Their Bets Across Pain Therapeutics?
10:00 am
- Which pain targets, technologies and therapeutic approaches are attracting the greatest investment interest today?
- What data package is required to move a program from scientific promise to an investable opportunity?
- How are investors assessing technical, clinical and commercial risk in an increasingly competitive pain landscape?
- Where do investors see the biggest opportunities and unmet needs shaping the next wave of pain innovation?
Thursday 28th January 2027
Fireside Chat: What Will Pharma Buy Next in Pain?
4:30 pm
- Assess how recent transactions, including Lilly’s acquisitions of SiteOne Therapeutics and 4E Therapeutics, and AbbVie’s licensing agreement with Haisco Pharmaceutical for HSK21542, are reshaping partnering and investment priorities across pain
- Define the translational, clinical and commercial evidence packages required to progress from early interest to competitive deal activity
- Explore which mechanisms, indications and patient populations are attracting the strongest external interest, from NaV1.8 inhibitors and peripheral targets through to neuroimmune and disease-modifying approaches
- Identify what differentiates a partnerable pain asset today, including target validation, patient selection strategy, clinical positioning and commercial potential
